B3(Fab)-streptavidin tetramer has higher binding avidity than B3(scFv)-streptavidin tetramer

Jae Seon Won, Hye Won Kang, Pil Won Nam, MuHyeon Choe

Research output: Contribution to journalArticle

Abstract

Multivalent and multi-specific antibodies can provide valuable tools for bio-medical research, diagnosis and therapy. In antigen-antibody interactions, the avidity of antibodies depends on the affinity and the number of binding sites. 1 As artificial multivalent antibody agents, single chain Fv-streptavidin fusion tetramer proteins (scFv-SA) 4 have been previously tested. 1,2 Although, the Fab domain is known to be more stable than scFv in animal models, 3,4 it has never been used to make a multivalent agent with a streptavidin fusion. In this study, we prepared tetra-valent (Fab-cSA) 4 by fusing Fab with core streptavidin (cSA). This molecule was made using inclusion body production, refolding and chromatography purification. Affinities of the Fab-cSA tetramer and a scFv-cSA tetramer to a cell surface antigen were compared by ELISA using biotin-HRP. The Fab-cSA tetramer showed higher binding avidity than the scFv-cSA tetramer. The higher binding avidity of the Fab-cSA tetramer demonstrates its potential as a therapeutic agent for target-specific antibody therapy.

Original languageEnglish
Pages (from-to)1101-1106
Number of pages6
JournalBulletin of the Korean Chemical Society
Volume30
Issue number5
DOIs
Publication statusPublished - 2009 Oct 13

Fingerprint

Streptavidin
Antibodies
Fusion reactions
Single-Chain Antibodies
Surface Antigens
Biotin
Chromatography
Purification
Animals
Binding Sites
Antigens
Molecules

Keywords

  • Antibody therapy
  • Fab
  • Homo-tetramer
  • Recombinant antibody
  • Refolding

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

B3(Fab)-streptavidin tetramer has higher binding avidity than B3(scFv)-streptavidin tetramer. / Won, Jae Seon; Kang, Hye Won; Nam, Pil Won; Choe, MuHyeon.

In: Bulletin of the Korean Chemical Society, Vol. 30, No. 5, 13.10.2009, p. 1101-1106.

Research output: Contribution to journalArticle

@article{0126326bf5314ae998b1c61247a5818f,
title = "B3(Fab)-streptavidin tetramer has higher binding avidity than B3(scFv)-streptavidin tetramer",
abstract = "Multivalent and multi-specific antibodies can provide valuable tools for bio-medical research, diagnosis and therapy. In antigen-antibody interactions, the avidity of antibodies depends on the affinity and the number of binding sites. 1 As artificial multivalent antibody agents, single chain Fv-streptavidin fusion tetramer proteins (scFv-SA) 4 have been previously tested. 1,2 Although, the Fab domain is known to be more stable than scFv in animal models, 3,4 it has never been used to make a multivalent agent with a streptavidin fusion. In this study, we prepared tetra-valent (Fab-cSA) 4 by fusing Fab with core streptavidin (cSA). This molecule was made using inclusion body production, refolding and chromatography purification. Affinities of the Fab-cSA tetramer and a scFv-cSA tetramer to a cell surface antigen were compared by ELISA using biotin-HRP. The Fab-cSA tetramer showed higher binding avidity than the scFv-cSA tetramer. The higher binding avidity of the Fab-cSA tetramer demonstrates its potential as a therapeutic agent for target-specific antibody therapy.",
keywords = "Antibody therapy, Fab, Homo-tetramer, Recombinant antibody, Refolding",
author = "Won, {Jae Seon} and Kang, {Hye Won} and Nam, {Pil Won} and MuHyeon Choe",
year = "2009",
month = "10",
day = "13",
doi = "10.5012/bkcs.2009.30.5.1101",
language = "English",
volume = "30",
pages = "1101--1106",
journal = "Bulletin of the Korean Chemical Society",
issn = "0253-2964",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - B3(Fab)-streptavidin tetramer has higher binding avidity than B3(scFv)-streptavidin tetramer

AU - Won, Jae Seon

AU - Kang, Hye Won

AU - Nam, Pil Won

AU - Choe, MuHyeon

PY - 2009/10/13

Y1 - 2009/10/13

N2 - Multivalent and multi-specific antibodies can provide valuable tools for bio-medical research, diagnosis and therapy. In antigen-antibody interactions, the avidity of antibodies depends on the affinity and the number of binding sites. 1 As artificial multivalent antibody agents, single chain Fv-streptavidin fusion tetramer proteins (scFv-SA) 4 have been previously tested. 1,2 Although, the Fab domain is known to be more stable than scFv in animal models, 3,4 it has never been used to make a multivalent agent with a streptavidin fusion. In this study, we prepared tetra-valent (Fab-cSA) 4 by fusing Fab with core streptavidin (cSA). This molecule was made using inclusion body production, refolding and chromatography purification. Affinities of the Fab-cSA tetramer and a scFv-cSA tetramer to a cell surface antigen were compared by ELISA using biotin-HRP. The Fab-cSA tetramer showed higher binding avidity than the scFv-cSA tetramer. The higher binding avidity of the Fab-cSA tetramer demonstrates its potential as a therapeutic agent for target-specific antibody therapy.

AB - Multivalent and multi-specific antibodies can provide valuable tools for bio-medical research, diagnosis and therapy. In antigen-antibody interactions, the avidity of antibodies depends on the affinity and the number of binding sites. 1 As artificial multivalent antibody agents, single chain Fv-streptavidin fusion tetramer proteins (scFv-SA) 4 have been previously tested. 1,2 Although, the Fab domain is known to be more stable than scFv in animal models, 3,4 it has never been used to make a multivalent agent with a streptavidin fusion. In this study, we prepared tetra-valent (Fab-cSA) 4 by fusing Fab with core streptavidin (cSA). This molecule was made using inclusion body production, refolding and chromatography purification. Affinities of the Fab-cSA tetramer and a scFv-cSA tetramer to a cell surface antigen were compared by ELISA using biotin-HRP. The Fab-cSA tetramer showed higher binding avidity than the scFv-cSA tetramer. The higher binding avidity of the Fab-cSA tetramer demonstrates its potential as a therapeutic agent for target-specific antibody therapy.

KW - Antibody therapy

KW - Fab

KW - Homo-tetramer

KW - Recombinant antibody

KW - Refolding

UR - http://www.scopus.com/inward/record.url?scp=70349752071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349752071&partnerID=8YFLogxK

U2 - 10.5012/bkcs.2009.30.5.1101

DO - 10.5012/bkcs.2009.30.5.1101

M3 - Article

AN - SCOPUS:70349752071

VL - 30

SP - 1101

EP - 1106

JO - Bulletin of the Korean Chemical Society

JF - Bulletin of the Korean Chemical Society

SN - 0253-2964

IS - 5

ER -